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Lithium therapy has been associated with several endocrine disorders including thyroid dysfunction, diabetes insipidus, and
hyperparathyroidism. While its suppressive eﬀect on thyroid function is well known, it is very rare to observe lithium-induced
hyperthyroidism especially in the pediatric population. Here, we describe a case of lithium-induced hyperthyroidism in an
adolescent female with bipolar disorder. The patient is a 17-year-old female who was treated with lithium for bipolar disorder and
presented with symptoms and laboratory ﬁndings consistent with hyperthyroidism. Since thyroid autoantibodies were negative,
thyroid dysfunction was attributed to lithium toxicity. Indeed, her clinical and biochemical hyperthyroid state resolved after
stopping lithium therapy. Lithium-associated hyperthyroidism can occur in the pediatric population. We propose close
monitoring of thyroid hormone levels in children on lithium therapy.

1. Case Report

2. Methods

Bipolar disorders are common in adolescents, with a lifetime
prevalence of 2.5% [1] and 0.1% in children aged 9–13 years
[2]. Lithium is commonly used for the treatment of bipolar
disorders in children and adolescents [3]. It has been associated with several endocrine disorders including thyroid
dysfunction, diabetes insipidus, and hyperparathyroidism.
Its suppressive eﬀect on thyroid function is well known; in
contrast, lithium-induced hyperthyroidism is rare with a
prevalence in the range of between 1% and 1.7% in the adult
population [4, 5]. The ﬁrst case of thyrotoxicosis in a patient
treated with lithium was reported in 1974 [6]. Hyperthyroidism in lithium-treated patients has been associated with
diﬀuse goiter, toxic multinodular goiter, and painless thyroiditis [7]. Lithium is also implicated in granulomatous
thyroiditis, and it is reported to induce auto-antibody formation and autoimmunity in susceptible individuals [8].
There have not been any cases reported about lithium-induced hyperthyroidism in pediatric population. We are
presenting an adolescent girl treated with lithium who
presented with hyperthyroidism.

Retrospective chart review of the case study was carried out.
Since it is a single case report, an approval from the Institutional Review Board (IRB) and consent are not required.
However, when a new patient is seen in our clinic, the family
signed a consent form for treatment and possible use of any
clinical ﬁnding to report anonymously.

3. Case Presentation
Our patient is a 17-year-5-month-old female with bipolar
disorder who was treated with lithium. She had been
placed on Concerta, Abilify, and Lamictal before being
switched to lithium monotherapy due to the limited
success of these initial therapies. She responded well to
lithium for two years until about 3-4 weeks prior to
presentation, when she developed dizziness, heat intolerance, excessive sweating, tremors, and palpitations. Due
to these symptoms, she stopped taking lithium and sought
medical attention at her primary care provider’s (PCP’s)
oﬃce. The PCP ordered laboratory tests which revealed a

2

Case Reports in Endocrinology

Table 1: Hormonal proﬁle of the patient with gradual improvements of thyroid hormone levels from being hyperthyroid to euthyroid.
Timeline
Initial lab work
2 days later
2 weeks later
1 month later
2 months
3 months
5 months
7 months

TSH
(0.35–5.5 mcIU/mL)
0.01
<0.02
<0.02
<0.02
<0.02
0.39
2.61
2.62

`suppressed TSH (<0.02 mcIU/mL, normal range:
0.35–5.50) and an elevated free T4 (3.5 ng/dL, normal
range: 0.8–1.9), both consistent with hyperthyroidism. Her
lithium level at that time was <0.3 (normal range:
0.6–1.2 mmol/L), likely due to noncompliance during the
past two weeks. The PCP received these results on the
weekend, and the patient was referred to the emergency
department (ED) where, on examination, she was tachycardic (140 bpm), afebrile, and her blood pressure was 132/
84 mmHg. Her thyroid exam revealed the presence of a
nontender goiter; no nodules were palpable. Repeat laboratory tests at the ED conﬁrmed biochemical hyperthyroidism (TSH: <0.02 mcIU/mL, total T3: 351 ng/dl, normal
range: 55 to 209) and an elevated free T4 (3.7 ng/dL). There
was a prolonged QT interval on her EKG. Of note, our
patient had no family history of autoimmunity or thyroid
disease. Thyroid suppressive therapy was initiated with
methimazole, 10 mg PO 3 times a day (0.46 mg/kg/day) as
advised by the endocrinologist. She was also started on
propranolol (60 mg/day∼0.92 mg/kg/day). The ESR, CRP,
CBC, and BMP were normal. Thyroid autoantibodies
(antithyroid peroxidase antibody, antithyroglobulin antibody, and thyroid stimulating immunoglobulin) were all
negative. She was advised not to restart lithium and
consult her psychiatrist. She was seen in the endocrine
clinic about two weeks later, after being oﬀ-lithium for
four weeks; her hyperthyroid symptoms had improved;
however, she still had palpitations and heat intolerance,
while her heart rate and blood pressure were still above the
age appropriate ranges (101 bpm and 133/74 mm hg, respectively). She had mild tongue fasciculation but no
exophthalmos. Repeat thyroid function tests showed a
lower free T4 level (2.0 ng/dl) as compared with two weeks
ago, while the TSH was still suppressed. A subsequent
endocrine visit two weeks later showed a normalized free
T4 (1.5 ng/dl) and improved clinical hyperthyroidism. As a
result, propranolol was discontinued, while methimazole
treatment was maintained. By three months after her
initial presentation, the methimazole dose was reduced
(10 mg b.i.d.) due to a borderline-low (0.8 ng/dl, normal
range of 0.8 to 1.9 ng/dL), Methimazole was eventually
discontinued after ﬁve months of initial presentation. At
her last follow-up in the endocrine clinic (seven months
after diagnosis of hyperthyroidism and several weeks after
stopping methimazole), she was clinically and biochemically euthyroid (Table 1).

Free T4
(0.9–1.9 ng/dL)
3.5
3.7
2.0
1.5
0.9
0.8
1.2
1.1

Total T3
(55–209 ng/dL)
351

188
175
172
134

4. Discussion
The prevalence of bipolar disorders in adolescence ranges
between 1.8% and 2.5% [9, 10]. They are considered as the
fourth leading cause of disability among adolescent
worldwide. In children with bipolar disorders, lithium is the
only mood stabilizer approved by the FDA for acute mania
and maintenance treatment [11]. In a recent meta-analysis
of studies on the eﬀects of lithium on thyroid function, the
investigators compared the prevalence of hypothyroidism
in patients treated with lithium with controls. The overall
odds of clinical hypothyroidism were close to six times
greater in lithium-treated subjects than in controls. Conversely, this study did not ﬁnd any diﬀerence between
patients and controls on lithium with respect to the
prevalence of increased thyroid function [4]. On the contrary, lithium-induced hyperthyroidism is rare even in
adults [12]; it is estimated to have the annual incidence of
0.1% [13]. Other studies have estimated the prevalence to be
in the range of 1%–1.7% [5, 14]. Only a small number of
children treated with lithium present with subclinical or
clinical hypothyroidism, and/or goiter [15, 16], to our
knowledge, ours is the ﬁrst case of a pediatric patient with
lithium-induced hyperthyroidism. The possible mechanism
regarding lithium-induced hyperthyroidism is thought to
be due to an expansion of the intrathyroidal iodine pool,
induction of autoimmune hyperthyroidism (Graves’ disease), and a toxic thyroid nodule or painless thyroiditis
[7, 17]. In patients with primary aﬀective disorders, thyroid
autoantibodies were detected in 8 of 40 subjects treated with
lithium, and only in 3 patients were treated with other
psychotropic drugs. Furthermore, the lithium-treated patients exhibited signiﬁcantly reduced numbers of suppressor and or cytotoxic T cells and increased B cell activity
compared to those treated with drugs other than lithium
[18]. Similar to amiodarone-induced toxic thyroiditis,
painless thyroiditis may also be the result of a direct toxic
eﬀect of lithium on the thyroid, which seems to be the likely
mechanism in our patient, in whom results of tests for
thyroid antibodies remained negative. Furthermore, it has
been reported that lithium-associated silent thyroiditis
occurred with an incidence rate of approximately 1.3 cases
per 1000 person-years, and lithium-associated thyrotoxicosis occurred with an incidence rate of approximately 2.7
cases per 1000 person-years, higher than the reported incidence rates of silent thyroiditis (<0.03–0.28 cases per 1000
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person-years) and of thyrotoxicosis (0.8–1.2 cases per 1000
person-years) in the general population and calculated the
odds of lithium exposure to be 4.7-fold higher in patients
with thyroiditis [7]. Recently, a meta-analysis of 52 studies
showed in nine of these that were cross-sectional or cohort
studies describing around 2500 patients that 2.6% patients
were hypothyroid [19]. Another cross-sectional study reported just one patient (1.2%) in their lithium-treated group
[20]. The histopathological features of the thyroid gland
showed an immunological phenomenon with lymphoid
follicles and ﬁbrosis in aﬀected thyroid glands [21], and this
autoimmune process was not detected in other prospective
studies, pre- and postlithium treatment [22, 23]. In our
patient, the thyroid antibodies were negative; CBC, C-reactive protein (CRP), and sedimentation rate (ESR) were
normal, suggesting that a mild silent thyroiditis may have
been the cause of hyperthyroidism. Miller and Daniels
described that most hyperthyroid patients had serum
lithium level in the therapeutic range [7]. However, our
patient’s lithium level was not elevated due to discontinuation of treatment 2 weeks before the levels were checked.
The duration of lithium therapy in patients who develop
hyperthyroidism and lithium-associated silent thyroiditis
range between 6 days and 15 years. However, in some cases,
thyrotoxicosis occurred 4 days to 5 months after withdrawal
of lithium therapy [24], and in our patient, the duration of
lithium therapy was about 2 years. In conclusion, lithiuminduced hyperthyroidism is very rarely diagnosed in adults
and has never been reported in children before our case. We
believe it is necessary to increase awareness of the possibility
of such drug-induced thyroid dysfunction in the pediatric
population, especially in children with hyperthyroidism and
negative thyroid autoantibodies. The transient nature of this
disorder is associated with a better prognosis compared to
patients with Graves’ disease. Since lithium-induced hyperthyroidism may occur even after years of lithium
therapy, it is advisable to regularly monitor the thyroid
function in children during the whole duration of lithium
treatment.
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